To test for a role for GART in adaptive immune responses associated with susceptibility to severe COVID-19, we used the GART inhibitory drug lometrexol in an in vitro human tonsillar organoid model of T cell-dependent germinal center B cell differentiation [32]. This evidence concerns the gene GART and COVID-19.